SMP200900027B - Compositions and method for modulating c-kit and pdgfr receptors - Google Patents

Compositions and method for modulating c-kit and pdgfr receptors

Info

Publication number
SMP200900027B
SMP200900027B SM200900027T SM200900027T SMP200900027B SM P200900027 B SMP200900027 B SM P200900027B SM 200900027 T SM200900027 T SM 200900027T SM 200900027 T SM200900027 T SM 200900027T SM P200900027 B SMP200900027 B SM P200900027B
Authority
SM
San Marino
Prior art keywords
modulating
kit
compositions
pdgfr receptors
pdgfr
Prior art date
Application number
SM200900027T
Other languages
Italian (it)
Other versions
SMAP200900027A (en
Inventor
Zuosheng Liu
Pingda Ren
Donatella Chianelli
Christopher Cow
Yun He
Songchun Jiang
Xiaolin Li
Xiaodong Liu
Jon Loren
Valentina Molteni
Juliet Nabakka
Taebo Sim
Xiaodong Wang
Shuli You
Original Assignee
Irm Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39027274&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SMP200900027(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Irm Llc filed Critical Irm Llc
Publication of SMAP200900027A publication Critical patent/SMAP200900027A/en
Publication of SMP200900027B publication Critical patent/SMP200900027B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Addiction (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
SM200900027T 2006-10-20 2009-04-20 Compositions and method for modulating c-kit and pdgfr receptors SMP200900027B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US86243006P 2006-10-20 2006-10-20
PCT/US2007/081538 WO2008051757A1 (en) 2006-10-20 2007-10-16 Compositions and methods for modulating c-kit and pdgfr receptors

Publications (2)

Publication Number Publication Date
SMAP200900027A SMAP200900027A (en) 2009-07-14
SMP200900027B true SMP200900027B (en) 2010-01-19

Family

ID=39027274

Family Applications (1)

Application Number Title Priority Date Filing Date
SM200900027T SMP200900027B (en) 2006-10-20 2009-04-20 Compositions and method for modulating c-kit and pdgfr receptors

Country Status (25)

Country Link
US (2) US7678792B2 (en)
EP (1) EP2076513A1 (en)
JP (1) JP2010506948A (en)
KR (1) KR101079520B1 (en)
CN (1) CN101528744A (en)
AR (1) AR063343A1 (en)
AU (1) AU2007309279B2 (en)
BR (1) BRPI0718162A2 (en)
CA (1) CA2667010A1 (en)
CL (1) CL2007003005A1 (en)
CO (1) CO6170361A2 (en)
CR (1) CR10717A (en)
EA (1) EA200900573A1 (en)
EC (1) ECSP099353A (en)
IL (1) IL197875A0 (en)
MA (1) MA30888B1 (en)
MX (1) MX2009004141A (en)
NI (1) NI200900061A (en)
NO (1) NO20091949L (en)
PE (1) PE20081262A1 (en)
SM (1) SMP200900027B (en)
TN (1) TN2009000145A1 (en)
TW (1) TW200825081A (en)
WO (1) WO2008051757A1 (en)
ZA (1) ZA200902711B (en)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2477604A1 (en) 2002-03-13 2003-09-25 Signum Biosciences, Inc. Modulation of protein methylation and phosphoprotein phosphate
EP1843734A4 (en) 2005-02-03 2008-09-10 Signum Biosciences Inc Compositions and methods for enhancing cognitive function
US7923041B2 (en) 2005-02-03 2011-04-12 Signum Biosciences, Inc. Compositions and methods for enhancing cognitive function
US7897762B2 (en) 2006-09-14 2011-03-01 Deciphera Pharmaceuticals, Llc Kinase inhibitors useful for the treatment of proliferative diseases
US8188113B2 (en) * 2006-09-14 2012-05-29 Deciphera Pharmaceuticals, Inc. Dihydropyridopyrimidinyl, dihydronaphthyidinyl and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
KR20140032505A (en) 2006-11-09 2014-03-14 알콘 리서치, 리미티드 Water insoluble polymer matrix for drug delivery
TWI498115B (en) * 2007-12-27 2015-09-01 Daiichi Sankyo Co Ltd Imidazole carbonyl compounds
ATE551342T1 (en) * 2008-02-22 2012-04-15 Irm Llc HETEROCYCLIC COMPOUNDS AND COMPOSITIONS AS C-KIT AND PDGFR KINASE INHIBITORS
CN102014897B (en) 2008-04-21 2015-08-05 西格纳姆生物科学公司 Compound, compositions and its preparation method
FR2930552B1 (en) * 2008-04-24 2012-10-12 Centre Nat Rech Scient N-ACYLTHIOUREES AND N-ACYLUREES INHIBITORS OF THE HEDGEHOG PROTEIN SIGNALING PATHWAY
US20110144107A1 (en) * 2008-06-11 2011-06-16 Irm Llc Compounds and compositions useful for the treatment of malaria
WO2010017331A1 (en) * 2008-08-05 2010-02-11 George Mason Intellectual Properties, Inc. Signal pathway alterations and drug target elevations in primary metachronous metastatic colorectal cancer compared to non-metastatic disease
BRPI0920765A2 (en) * 2008-10-29 2015-08-18 Deciphera Pharmaceuticals Llc Cilopropane amides and analogs that exhibit anticancer and antiproliferative activities
AR074776A1 (en) * 2008-12-18 2011-02-09 Sanofi Aventis METHOD TO TREAT MACULAR DEGENERATION; MODULATING THE PATIENT'S IMMUNE SYSTEM
WO2010071846A2 (en) 2008-12-19 2010-06-24 Afraxis, Inc. Compounds for treating neuropsychiatric conditions
CA2751517A1 (en) * 2009-02-13 2010-08-19 Fovea Pharmaceuticals [1, 2, 4] triazolo [1, 5 -a] pyridines as kinase inhibitors
US8372970B2 (en) 2009-10-09 2013-02-12 Afraxis, Inc. 8-ethyl-6-(aryl)pyrido[2,3-D]pyrimidin-7(8H)-ones for the treatment of CNS disorders
BR112012018865A2 (en) 2010-01-29 2016-04-12 Boehringer Ingelheim Int substituted naphthyridines and their use as syk kinase inhibitors
US9181238B2 (en) 2010-02-05 2015-11-10 Novartis Ag N-(pyridin-2-yl)sulfonamides and compositions thereof as protein kinase inhibitors
WO2012103165A2 (en) * 2011-01-26 2012-08-02 Kolltan Pharmaceuticals, Inc. Anti-kit antibodies and uses thereof
AU2012249801B2 (en) * 2011-04-25 2016-05-19 Usher Iii Initiative, Inc. Pyrazolopyridazines and methods for treating retinal-degenerative diseases and hearing loss associated with Usher syndrome
CN103827090B (en) 2011-07-26 2016-04-20 勃林格殷格翰国际有限公司 The quinoline replaced and the purposes as medicine thereof
BR112014007599A2 (en) * 2011-09-30 2017-04-11 Kineta Inc antiviral compounds
AU2013261128B2 (en) 2012-05-15 2015-11-12 Novartis Ag Benzamide derivatives for inhibiting the activity of ABL1, ABL2 and BCR-ABL1
WO2013171642A1 (en) 2012-05-15 2013-11-21 Novartis Ag Benzamide derivatives for inhibiting the activity of abl1, abl2 and bcr-abl1
BR112014027584B1 (en) 2012-05-15 2023-01-24 Novartis Ag USE OF INHIBITORS OF ABL1, ABL2 AND BCR-ABL1 ACTIVITY, AND PHARMACEUTICAL COMPOSITION
SI2861579T1 (en) 2012-05-15 2018-05-31 Novartis Ag Benzamide derivatives for inhibiting the activity of abl1, abl2 and bcr-abl1
US8461179B1 (en) 2012-06-07 2013-06-11 Deciphera Pharmaceuticals, Llc Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
ES2663605T3 (en) * 2012-06-07 2018-04-16 Deciphera Pharmaceuticals, Llc Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
NZ630363A (en) 2012-07-25 2018-09-28 Celldex Therapeutics Inc Anti-kit antibodies and uses thereof
US9227976B2 (en) 2012-10-25 2016-01-05 Usher Iii Initiative, Inc. Pyrazolopyridazines and methods for treating retinal-degenerative diseases and hearing loss associated with usher syndrome
AU2014302458A1 (en) * 2013-06-26 2015-12-24 Proteostasis Therapeutics, Inc. Methods of modulating CFTR activity
GB201401886D0 (en) 2014-02-04 2014-03-19 Lytix Biopharma As Neurodegenerative therapies
CA2942386A1 (en) 2014-03-13 2015-09-17 Proteostasis Therapeutics, Inc. Compounds, compositions, and methods for increasing cftr activity
US9745292B2 (en) 2014-03-13 2017-08-29 Proteostasis Therapeutics, Inc. Compounds, compositions, and methods for increasing CFTR activity
JP6768639B2 (en) 2014-05-23 2020-10-21 セルデックス セラピューティクス，インコーポレーテッド Treatment of eosinophil or mast cell related disorders
EP3157917B1 (en) 2014-06-19 2020-03-18 Proteostasis Therapeutics, Inc. Compounds, compositions and methods of increasing cftr activity
CN111170998B (en) 2014-11-05 2023-04-11 益方生物科技(上海)股份有限公司 Pyrimidine or pyridine compound, preparation method and medical application thereof
US10738011B2 (en) 2014-12-23 2020-08-11 Proteostasis Therapeutics, Inc. Derivatives of 5-(hetero)arylpyrazol-3-carboxylic amide or 1-(hetero)aryltriazol-4-carboxylic amide useful for the treatment of inter alia cystic fibrosis
CA2971850A1 (en) 2014-12-23 2016-06-30 Proteostasis Therapeutics, Inc. Derivatives of 5-phenyl- or 5-heteroarylthiazol-2-carboxylic amide useful for the treatment of inter alia cystic fibrosis
MA41253A (en) 2014-12-23 2017-10-31 Proteostasis Therapeutics Inc COMPOUNDS, COMPOSITIONS AND PROCESSES TO INCREASE THE ACTIVITY OF CFTR
US10344023B2 (en) 2014-12-23 2019-07-09 Proteostasis Therapeutics, Inc. Derivatives of 3-heteroarylisoxazol-5-carboxylic amide useful for the treatment of inter alia cystic fibrosis
US10548878B2 (en) 2015-07-24 2020-02-04 Proteostasis Therapeutics, Inc. Compounds, compositions, and methods of increasing CFTR activity
CN105664178B (en) * 2015-09-24 2019-08-20 洪健 SYK is as the application of liver fibrosis/hardening treating target spot
WO2017062581A1 (en) 2015-10-06 2017-04-13 Proteostasis Therapeutics, Inc. Compounds, compositions, and methods for modulating cftr
CN107286077B (en) 2016-04-01 2021-04-02 合肥中科普瑞昇生物医药科技有限公司 Selective C-KIT kinase inhibitor
CN109563047A (en) 2016-04-07 2019-04-02 蛋白质平衡治疗股份有限公司 Containing silicon atom according to cutting down Kato analog
MA45397A (en) 2016-06-21 2019-04-24 Proteostasis Therapeutics Inc COMPOUNDS, COMPOSITIONS AND PROCESSES TO INCREASE THE ACTIVITY OF CFTR
US11028064B2 (en) * 2016-11-04 2021-06-08 Auckland Uniservices Limited Tricyclic heterocyclic derivatives and uses thereof
CA3056886A1 (en) * 2017-03-21 2018-09-27 Arbutus Biopharma Corporation Substituted dihydroindene-4-carboxamides and analogs thereof, and methods using same
IL270525B2 (en) 2017-05-12 2024-06-01 Enanta Pharm Inc Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof
MX2019014343A (en) * 2017-05-30 2020-08-03 Deciphera Pharmaceuticals Inc USE OF 1-[4-BROMO-5-[1-ETHYL-7-(METHYLAMINO)-2-OXO-1,2-DIHYDRO-1, 6-NAPHTHYRIDIN-3-YL]-2-FLUOROPHENYL]-3-PHENYLUREA AND ANALOGS FOR THE TREATMENT OF CANCERS ASSOCIATED WITH GENETIC ABNORMALITIES IN PLATELET DERIVED GROWTH FACTOR RECEPTOR <i>ALPHA.
CN111094286B (en) * 2017-09-20 2022-07-29 浙江海正药业股份有限公司 1, 2-dihydro-1, 6-naphthyridine derivatives, preparation method and medical application thereof
EP3684767B1 (en) 2017-09-22 2024-04-24 Jubilant Epipad LLC Heterocyclic compounds as pad inhibitors
KR20200071752A (en) 2017-10-18 2020-06-19 주빌런트 에피파드 엘엘씨 Imidazo-pyridine compounds as PAD inhibitors
US11629135B2 (en) 2017-11-06 2023-04-18 Jubilant Prodell Llc Pyrimidine derivatives as inhibitors of PD1/PD-L1 activation
SG11202004537UA (en) 2017-11-24 2020-06-29 Jubilant Episcribe Llc Heterocyclic compounds as prmt5 inhibitors
SG11202007198WA (en) 2018-01-31 2020-08-28 Deciphera Pharmaceuticals Llc Combination therapy for the treatment of gastrointestinal stromal tumors
JP7279063B6 (en) * 2018-03-13 2024-02-15 ジュビラント プローデル エルエルシー Bicyclic compounds as inhibitors of PD1/PD-L1 interaction/activation
KR20210005195A (en) 2018-05-02 2021-01-13 이난타 파마슈티칼스, 인코포레이티드 Tetrazole comprising an apoptosis signal modulating kinase 1 inhibitor and methods of use thereof
US10968199B2 (en) * 2018-08-22 2021-04-06 Enanta Pharmaceuticals, Inc. Cycloalkyl-containing apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof
RU2771526C1 (en) * 2018-09-14 2022-05-05 Аббиско Терапеутикс Ко., Лтд. Fgfr inhibitor, method for production and application thereof
US11345699B2 (en) 2018-11-19 2022-05-31 Enanta Pharmaceuticals, Inc. Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof
WO2020198214A1 (en) 2019-03-25 2020-10-01 Enanta Pharmaceuticals, Inc. Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof
TW202122082A (en) 2019-08-12 2021-06-16 美商迪賽孚爾製藥有限公司 Methods of treating gastrointestinal stromal tumors
BR112022002609A2 (en) 2019-08-12 2022-08-09 Deciphera Pharmaceuticals Llc METHODS OF TREATMENT OF GASTROINTESTINAL STROMAL TUMORS
WO2021039791A1 (en) * 2019-08-25 2021-03-04 国立大学法人山口大学 Medicinal composition for preventing or treating angiogenesis-related diseases
KR20220123058A (en) 2019-12-30 2022-09-05 데시페라 파마슈티칼스, 엘엘씨. 1-(4-Bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluorophenyl ) -3-Phenylurea composition
IL293866A (en) 2019-12-30 2022-08-01 Deciphera Pharmaceuticals Llc Amorphous kinase inhibitor formulations and methods of use thereof
US20210315869A1 (en) * 2020-04-02 2021-10-14 Plexxikon Inc. Compounds and methods for csk modulation and indications therefor
BR112023009531A2 (en) 2020-11-18 2023-10-03 Deciphera Pharmaceuticals Llc GCN2 AND PERK KINASE INHIBITORS AND METHODS OF USE THEREOF
CN115108997A (en) * 2021-03-22 2022-09-27 南开大学 Synthesis and application of sulfonylurea compounds with antibacterial activity
TW202317086A (en) * 2021-09-29 2023-05-01 加拿大商修復治療公司 Compounds, pharmaceutical compositions, and methods of preparing compounds and of their use
US11814384B2 (en) 2022-02-03 2023-11-14 Kinnate Biopharma Inc. Inhibtors of Raf kinases
WO2024039864A1 (en) * 2022-08-19 2024-02-22 Purdue Research Foundation Protein:protein interaction inhibitors
US11779572B1 (en) 2022-09-02 2023-10-10 Deciphera Pharmaceuticals, Llc Methods of treating gastrointestinal stromal tumors

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001292320A1 (en) 2000-10-02 2002-04-15 Tanabe Seiyaku Co., Ltd. Benzylamine compound, process for producing the same, and intermediate therefor
CA2542105C (en) * 2003-10-08 2011-08-02 Irm Llc Compounds and compositions as protein kinase inhibitors
AU2005321946B2 (en) * 2004-12-23 2012-08-16 Deciphera Pharmaceuticals, Llc Enzyme modulators and treatments
WO2006081034A2 (en) * 2004-12-23 2006-08-03 Deciphera Pharmaceuticals, Llc Anti-inflammatory medicaments
RU2008149245A (en) 2006-05-15 2010-06-20 Айрм Ллк (Bm) COMPOSITIONS AND METHODS FOR INHIBITING RECEPTOR KINASES FGF
US8188113B2 (en) * 2006-09-14 2012-05-29 Deciphera Pharmaceuticals, Inc. Dihydropyridopyrimidinyl, dihydronaphthyidinyl and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
JP5357763B2 (en) * 2006-11-06 2013-12-04 トレロ ファーマシューティカルズ， インコーポレイテッド Imidazo [1,2-b] pyridazine derivatives and pyrazolo [1,5-a] pyridazine derivatives and their use as protein kinase inhibitors

Also Published As

Publication number Publication date
TN2009000145A1 (en) 2010-10-18
US20100081656A1 (en) 2010-04-01
AU2007309279A1 (en) 2008-05-02
US20080176846A1 (en) 2008-07-24
AR063343A1 (en) 2009-01-21
WO2008051757A1 (en) 2008-05-02
IL197875A0 (en) 2009-12-24
ZA200902711B (en) 2010-05-26
PE20081262A1 (en) 2008-10-29
CN101528744A (en) 2009-09-09
NI200900061A (en) 2010-03-10
US7678792B2 (en) 2010-03-16
EP2076513A1 (en) 2009-07-08
MA30888B1 (en) 2009-11-02
CL2007003005A1 (en) 2008-05-23
SMAP200900027A (en) 2009-07-14
MX2009004141A (en) 2009-05-01
KR101079520B1 (en) 2011-11-03
CO6170361A2 (en) 2010-06-18
ECSP099353A (en) 2009-06-30
CA2667010A1 (en) 2008-05-02
AU2007309279B2 (en) 2011-03-24
US8106068B2 (en) 2012-01-31
CR10717A (en) 2009-07-02
EA200900573A1 (en) 2009-10-30
TW200825081A (en) 2008-06-16
BRPI0718162A2 (en) 2013-11-26
NO20091949L (en) 2009-05-19
JP2010506948A (en) 2010-03-04
KR20090054477A (en) 2009-05-29

Similar Documents

Publication Publication Date Title
SMP200900027B (en) Compositions and method for modulating c-kit and pdgfr receptors
CY2020024I2 (en) BETA-LACTAMAS INHIBITORS
CY2017016I2 (en) PROTEASOMY INHIBITORS
DK2041138T3 (en) PYRROLTRIAZINKINASE INHIBITORS
DK2086939T3 (en) Pyridiacarboxamide as II-beta-HSDI inhibitors
BRPI0811516A2 (en) COMPOUNDS AND COMPOSITIONS AS C-KIT AND PDGFR KINASE INHIBITORS
CR10831A (en) ESPIRO KETONA ACETIL-CoA CARBOXILASA INHIBITORS
BRPI0810365A2 (en) INDOL 7-REPLACED MLC-1 INHIBITORS
BRPI0817726A2 (en) Method
DK2125748T3 (en) Acylaminopyrazole as FGFR inhibitors
ATE549340T1 (en) SPIROINDOLINONE DERIVATIVES AS MDM2-P53 INHIBITORS
BRPI0919116A2 (en) method
BRPI0818003A2 (en) csf-1r inhibitors, compositions and methods of use
ATE467623T1 (en) DIAZEPAN-ACETAMIDE DERIVATIVES AS SELECTIVE 11-HSD1 INHIBITORS
DK2313489T3 (en) Method
BRPI0918564A2 (en) inhibitors
BRPI0812159A2 (en) csf-1r inhibitors, compositions and methods of use
FI20060178A0 (en) coating method
BRPI0811517A2 (en) COMPOUNDS AND COMPOSITIONS AS C-KIT AND PDGFR KINASE INHIBITORS.
DK2066662T3 (en) SERINHYDROLASE INHIBITORS
ZA200904920B (en) Benzimidazole TRPV1 inhibitors
DK2041088T3 (en) GLYCIN TRANSPORTER-1 INHIBITORS
BRPI0916597A2 (en) Method
BRPI0909106A2 (en) Herbicide Method
DK2069093T3 (en) Holds for scissors